ICo's IDEAL Trial Fails, What's Left For Investors?
- Top-line results of the much anticipated Phase 2 iDEAL trial with iCo-007 failed to show separation from the active controls.
- Full data is expected in the fourth quarter 2014. The company is hoping to show positive subset analysis in VEGF-refractory patients.
- Residual valuation for iCo-008 and iCo-009 lead us to conclude the stock is worth $0.15 per share.
- At this stage, risk and volatility remain high.